The United States Food and Drug Administration (FDA) has granted PhiloGene, Inc. orphan drug designation for their investigative agent VEGFb. The designation is for the treatment of patients with stages IIb through stage IV melanoma.
VEGFb (vascular endothelial growth factor “b”) is the native form of VEGF which possess anti-angiogenic properties. VEGFb is PhiloGene’s most advanced program, and received orphan drug status for a larger subset of melanoma than was requested.
© 1998-2007 OncoEd.com All Rights Reserved.
These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers should verify all information and data before administering any drug, therapy or treatment discussed herein. Neither the editors nor the publisher accepts any responsibility for the accuracy of the information or consequences from the use or misuse of the information contained herein.
Patient Home
